ClinicalTrials.gg
CompletedNCT06278389Updated Aug 14, 2026

Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants

A Phase 1 interventional study of ACC017 tablets and Emtricitabine and Tenofovir Alafenamide Fumarate Tablets in Healthy Adult Participants, sponsored by Jiangsu Aidea Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The objective of this clinical trial is to investigate the safety and tolerability of single ascending dose ACC017 tablets in Chinese healthy adult participants. This study aims to address the following major questions:

  • Recommended dosage for ACC017 tablets used in phase Ib/IIa trial;
  • The pharmacokinetic (PK) characteristics of single dose ACC017 tablets;
  • The effect of food (FE) on the PK of ACC017 tablets;
  • Drug-drug interactions (DDIs) when ACC017 tablets are co-administered with emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) tablets (II).
Read the detailed description

This is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD), two-stage, phase Ia clinical trial in Chinese healthy adults to evaluate the safety, tolerability, PK, FE, and DDIs with FTC/TAF of ACC017 tablets administered as a single dose in healthy participants.

The trial will be divided into two stages: the first stage is a single-center, randomized, double-blind, placebo-controlled SAD study. The study consists of six dose cohorts, namely, 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg cohorts (whether to escalate to the 160 mg cohort will be determined or adjusted if applicable) (D2\~D7), and a subsequent discharge visit (D8). Participants will receive a single oral dose of ACC017 tablets or placebo under fasting conditions.

The second stage is a single-center, randomized, open-label FE and DDI study with a tentative dose of 40 mg. The final administered dose will be determined after completion of the SAD study, as assessed by the investigator and the sponsor. Stage 2 is planned to enroll 12 healthy participants (both males and females), who are randomly assigned at a 1:1 ratio to either the fasting-postprandial group (F-P group) or the postprandial-fasting group (P-F group), with 6 participants in each group. Eligible healthy participants are admitted on D-1 and receive a single oral dose of ACC017 tablets on the day of administration of each cycle under the fasting or postprandial condition, with a washout period of 7 days during the two-week period. After completing the second cycle of drug washout, participants are evaluated by the investigator and enter into the DDI study and receive a single oral dose of ACC017 tablets with FTC/TAF tablets under fasting condition.

The study is divided into screening period (no more than 28 days, D-28 to D-1), FE first cycle (D1), washout period A (D2 to D7), FE second cycle (D8), washout period B (D9 to D14), DDI period (D15), wahout period C (D16 to D21), and discharge (D22) visits.

02

Conditions studied

  • Healthy Adult Participants
03

In context

Lead sponsor

Jiangsu Aidea Pharmaceutical Group Co., Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteering to sign the and able to follow protocol-defined procedural requirements;
  2. Aged 18 to 55 years (inclusive);
  3. Male weighing ≥ 50.0 kg, female weighing ≥ 45.0 kg, and (BMI) = weight(kg)/height\^2 (m\^2) within the range of 18.5\~26 kg/m\^2 (inclusive);
  4. Women of (WOCBP) or men without a birth plan (including sperm or egg donation) and agreeing to use effective (including one or more non-pharmacological contraceptives or non-heterosexual sexual activity in daily life) from 1 month prior to informed consent up to 3 months after the last dose of the study medication;
  5. No history of significant medical or surgical illness, and normal results on vital signs, physical examination, 12-lead (ECG), laboratory tests, chest X-ray and abdominal ultrasound examination during the screening period, or minor deviations from normal reference values that are not in the judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Occurrence or persistence of abnormal conditions, including but not limited to cardiovascular, respiratory, gastrointestinal (any history of gastrointestinal disorders affecting the absorption of medications), urinary, hematologic and lymphatic, endocrine, musculoskeletal, immune, and neuropsychiatric disorders;
  2. Possible or definite allergic reaction to the study drug, placebo, or any of the contained, as judged by the investigator, or allergy (multiple drug and food sensitivities), or a history of allergic disease (e.g., asthma, urticaria, and eczematous dermatitis, etc.);
  3. Acute illness, such as respiratory tract infections requiring antibiotic treatment, occurring from screening until study drug administration;
  4. Inability to tolerate venipuncture, or history of needle-sickness or blood-sickness, or blood donation including component blood or significant blood loss (≥400 mL) or receipt of blood transfusion within 3 months prior to screening, or planning to donate blood during the trial period;
  5. Dysphagia, or surgery within 6 months prior to screening, or surgery planned during the trial, or surgery that interferes with the absorption, distribution, metabolism, or excretion of the medication;
  6. Smoking an average of >5 cigarettes per day within 3 months prior to screening, or inability to stop using any tobacco-based product during the trial period;
  7. Average weekly alcohol consumption greater than 14 units (1 unit of alcohol ≈ 360 mL of beer, or 45 mL of 40% (alcohol by volume) spirits, or 150 mL of wine) within 3 months prior to screening or inability to discontinue use of any alcohol-containing product during the trial period, or with a positive breath test for alcohol at screening;
  8. Excessive consumption of tea, coffee, and/or caffeinated beverages (more than 8 cups on average per day, 1 cup ≈ 250 mL) within 3 months prior to screening, or inability to stop consuming tea, coffee, and/or caffeinated beverages during the trial period;
  9. Consumption or drinking of dragon fruit, mango, grapefruit, popcorn, or foods or beverages prepared from the aforementioned fruits, or foods or beverages containing xanthines, caffeine, or alcohol (including chocolate, tea, coffee, cola, and cocoa), or any other special diet that interferes with the absorption, distribution, metabolism, or excretion of the drug, within 48 hours prior to administration of the study medication;
  10. With special dietary requirements, or cannot accept a uniform diet;
  11. Use of strong or moderate inhibitors (e.g., clarithromycin, telithromycin, ketoconazole, itraconazole and nefazodone, etc.) or strong CYP3A4 inducers (e.g., rifampicin, efavirenz, carbamazepine, phenobarbital, phenytoin, pioglitazone, St. John's wort, and , etc.) within 28 days or 5 half-lives (whichever is longer) before screening;
  12. Use of strong or moderate UGT1A inhibitors (e.g., silybin, ritonavir, atazanavir, quinidine, diclofenac, mycophenolic acid, and osimertinib, etc.) or strong UGT1A1 inducers (e.g., rifampicin, carbamazepine, phenobarbital, and phenytoin, etc.) within 28 days or 5 drug half-lives (whichever is longer) before screening;
  13. Use of any prescription drugs, over-the-counter drugs or Chinese (herbal) medicines within 14 days or 5 drug half-lives (whichever is longer) prior to screening;
  14. Vaccination (e.g., SARS-CoV-2 virus vaccine, and virus vaccine, etc.) within 1 month before screening, and are not suitable for enrollment as assessed by the investigator;
  15. Positive for hepatitis B surface antigen (HBsAg), or virus (HCV) antibody, or (HIV) antibody, or Tponema pallidum (Tp) antibody at screening;
  16. History of substance abuse within 5 years prior to screening, or positive urine drug screen at screening;
  17. Females who are pregnant or lactating at the time of screening, or have a positive blood pregnancy test (for only);
  18. Participation in any interventional clinical trials, including drugs, vaccines, or devices, etc., within 3 months prior to screening,;
  19. It is not suitable for a participant to participate in this trial in the judgment of the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Stage 1: ACC017 and placebo

    The trial is conducted sequentially from the low-dose cohorts, namely, 5 mg, 20 mg, 40 mg, 80 mg, 120 mg and 160 mg(tentative), respectively. Participants are given a single dose of ACC017 tablets or placebo under the fasting condition.

    Drug: ACC017 tablets

  • Experimental
    Stage 2: ACC017 and FTC/TAF (Descovy)

    Stage 2 is a single center, randomized, open-label FE and DDI study with a tentative dose of 40 mg. The stage was planned to enroll 12 healthy participants (both male and female) who are randomly assigned to either the fasting-postprandial or postprandial-fasting arm at a 1:1 ratio. Eligible healthy participants are admitted on D-1 and received a single oral dose of ACC017 tablets on the day of administration of each cycle under the fasting or postprandial condition with a washout period of 7 days during the two-week period. After completing the washout of the second cycle, participants are assessed by the investigator to enter into the DDI study and receive a single oral dose of ACC017 tablets with FTC/TAF tablets under the fasting condition.

    Drug: ACC017 tablets · Drug: Emtricitabine and Tenofovir Alafenamide Fumarate Tablets

Interventions

  • ACC017 tablets 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg (tentative) with matching placebo

    Also known as: ACC017/Placebo

  • DrugEmtricitabine and Tenofovir Alafenamide Fumarate Tablets

    Drug pages: Emtricitabine · Tenofovir alafenamide

    Participants received a single oral dose of ACC017 tablets with emtricitabine and tenofovir alafenamide fumarate tablets under the fasting condition.

    Also known as: Descovy

06

What researchers measure

Primary outcomes

  1. Frequency, causality, severity, and expectedness of adverse events (AEs)

    Includes Adverse Drug Reactions \[ADRs\], Grade 3 and above AEs, and Serious Adverse Events \[SAEs\], Serious Adverse Drug Reactions \[SADRs\], AEs resulting in treatment interruptions, AEs resulting in early withdrawal from the trial, and AEs of Special Interest \[AESI\]

    Time frame: Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  2. ACC017 PK parameter: Cmax (after a single mono-drug administration under the fasting condition)

    Cmax is defined as the maximum observed concentration of drug

    Time frame: Day 1 through Day 8 of Stage 1

  3. ACC017 PK parameter: C24h (after a single mono-drug administration under the fasting condition)

    C24h is defined as the plasma drug concentrations sampled 24 hours-post dose (C24h)

    Time frame: Day 1 through Day 8 of Stage 1

  4. ACC017 PK parameter: AUC0-t (after a single mono-drug administration under the fasting condition)

    AUC0-t is defined as area under the plasma concentration-time curve from time zero to the time of the last measurable plasma concentration

    Time frame: Day 1 through Day 8 of Stage 1

  5. ACC017 PK parameter: AUC0-∞ (after a single mono-drug administration under the fasting condition)

    AUC0-∞ is defined as AUC from time zero to infinity

    Time frame: Day 1 through Day 8 of Stage 1

  6. ACC017 PK parameter: Tmax (after a single mono-drug administration under the fasting condition)

    Tmax is defined as the time to reach Cmax

    Time frame: Day 1 through Day 8 of Stage 1

  7. ACC017 PK parameter: t1/2 (after a single mono-drug administration under the fasting condition)

    Half-life

    Time frame: Day 1 through Day 8 of Stage 1

  8. ACC017 PK parameter: Vz/F (after a single mono-drug administration under the fasting condition)

    Apparent volume of distribution during terminal phase after oral administration

    Time frame: Day 1 through Day 8 of Stage 1

  9. ACC017 PK parameter: CL/F (after a single mono-drug administration under the fasting condition)

    Apparent total plasma clearance of drug after oral administration

    Time frame: Day 1 through Day 8 of Stage 1

  10. ACC017 PK parameter: λz (after a single mono-drug administration under the fasting condition)

    Terminal elimination rate constant

    Time frame: Day 1 through Day 8 of Stage 1

  11. ACC017 PK parameter: AUC_%Extrap (after a single mono-drug administration under the fasting condition)

    Percentage of AUCinf due to extrapolation from Tlast to infinity

    Time frame: Day 1 through Day 8 of Stage 1

  12. ACC017 PK parameter: MRT0-t (after a single mono-drug administration under the fasting condition)

    MRT0-t is defined as the mean retention time from time zero to the time of the last measurable plasma concentration

    Time frame: Day 1 through Day 8 of Stage 1

  13. ACC017 PK parameter: MRT0-∞ (after a single mono-drug administration under the fasting condition)

    MRT0-∞ is defined as MRT from time zero to infinity

    Time frame: Day 1 through Day 8 of Stage 1

Secondary outcomes

  1. Vital signs: temperature

    Temperature in degree Celsius

    Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  2. Vital sign: pulse

    Pulse in beat per minute

    Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  3. Vital signs: blood pressure

    Systolic and diastolic blood pressure in millimeters (mm) of mercury (Hg)

    Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  4. Vital signs: respiration

    Respiratory rate in breaths per minute

    Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  5. Electrocardiogram (ECG): heart rate

    Heart rate in beat per minute

    Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  6. Electrocardiogram (ECG): PR interval

    Changes in PR interval

    Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  7. Electrocardiogram (ECG): QRS duration

    Changes in QRS duration

    Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  8. Electrocardiogram (ECG): QTc interval

    Changes in QTc interval

    Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  9. ACC017 PK parameter: Cmax

    ACC017 Cmax after single postprandial single-drug administration,ACC017 Cmax after a single coadministration under the fasting condition and FTC and TAF Cmax after a single coadministration under the fasting condition

    Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  10. ACC017 PK parameter: C24h

    ACC017 C24h after single postprandial single-drug administration,ACC017 C24h after a single coadministration under the fasting condition and FTC and TAF C24h after a single coadministration under the fasting condition

    Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  11. ACC017 PK parameter: AUC0-t

    ACC017 AUC0-t after single postprandial single-drug administration,ACC017 AUC0-t after a single coadministration under the fasting condition and FTC and TAF AUC0-t after a single coadministration under the fasting condition

    Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  12. ACC017 PK parameter: AUC0-∞

    ACC017 AUC0-∞ after single postprandial single-drug administration,ACC017 AUC0-∞ after a single coadministration under the fasting condition and FTC and TAF AUC0-∞ after a single coadministration under the fasting condition

    Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  13. ACC017 PK parameter: Tmax

    ACC017 Tmax after single postprandial single-drug administration,ACC017 Tmax after a single coadministration under the fasting condition and FTC and TAF Tmax after a single coadministration under the fasting condition

    Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  14. ACC017 PK parameter: t1/2

    ACC017 t1/2 after single postprandial single-drug administration,ACC017 t1/2 after a single coadministration under the fasting condition and FTC and TAF t1/2 after a single coadministration under the fasting condition

    Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  15. ACC017 PK parameter: Vz/F

    ACC017 Vz/F after single postprandial single-drug administration,ACC017 Vz/F after a single coadministration under the fasting condition and FTC and TAF Vz/F after a single coadministration under the fasting condition

    Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  16. ACC017 PK parameter: CL/F

    ACC017 CL/F after single postprandial single-drug administration,ACC017 CL/F after a single coadministration under the fasting condition and FTC and TAF CL/F after a single coadministration under the fasting condition

    Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  17. ACC017 PK parameter: λz

    ACC017 λz after single postprandial single-drug administration,ACC017 λz after a single coadministration under the fasting condition and FTC and TAF λz after a single coadministration under the fasting condition

    Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  18. ACC017 PK parameter: AUC_%Extrap

    ACC017 AUC\_%Extrap after single postprandial single-drug administration,ACC017 AUC\_%Extrap after a single coadministration under the fasting condition and FTC and TAF AUC\_%Extrap after a single coadministration under the fasting condition

    Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  19. ACC017 PK parameter: MRT0-t

    ACC017 MRT0-t after single postprandial single-drug administration,ACC017 MRT0-t after a single coadministration under the fasting condition and FTC and TAF MRT0-t after a single coadministration under the fasting condition

    Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

  20. ACC017 PK parameter: MRT0-∞

    ACC017 MRT0-∞ after single postprandial single-drug administration,ACC017 MRT0-∞ after a single coadministration under the fasting condition and FTC and TAF MRT0-∞ after a single coadministration under the fasting condition

    Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2

07

Study locations

1 site
  • Beijing Ditan Hospital Capital Medical University
    Beijing, 100015, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in May 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Feb 26, 2024
StartActual
Jan 24, 2024
Primary completionActual
May 20, 2024
CompletionActual
May 20, 2024
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06278389
Collaborators
Chengdu Aidea Pharmaceutical Technology Co., Ltd
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Jan 24, 2024
Primary completion
May 20, 2024
Completion
May 20, 2024
Last update
Aug 14, 2026

Study contacts

Fujie Zhang, M.D., Ph.D.
principal investigator · Beijing Ditan Hospital
Chaoying Hu, Ph.D.
principal investigator · Beijing Ditan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ACC017

Start the discussion